Can biomarkers help us hit targets in difficult-to-treat asthma?

Fricker, Michael, Heaney, Liam G. and Upham, John W. (2017) Can biomarkers help us hit targets in difficult-to-treat asthma?. Respirology, 22 3: 430-442. doi:10.1111/resp.13014


Author Fricker, Michael
Heaney, Liam G.
Upham, John W.
Title Can biomarkers help us hit targets in difficult-to-treat asthma?
Journal name Respirology   Check publisher's open access policy
ISSN 1440-1843
1323-7799
Publication date 2017-04-01
Sub-type Article (original research)
DOI 10.1111/resp.13014
Open Access Status Not yet assessed
Volume 22
Issue 3
Start page 430
End page 442
Total pages 13
Place of publication Richmond, VIC, Australia
Publisher Wiley-Blackwell Publishing Asia
Collection year 2018
Language eng
Abstract Biomarkers may be a key foundation for the precision medicine of the future. In this article, we review current knowledge regarding biomarkers in difficult-to-treat asthma and their ability to guide the use of both conventional asthma therapies and novel (targeted) therapies. Biomarkers (as measured by tests including prednisolone and cortisol assays and the fractional exhaled nitric oxide (NO) suppression test) show promise in the assessment and management of non-adherence to inhaled and oral corticosteroids. Multiple markers of type 2 inflammation have been developed, including eosinophils in sputum and blood, exhaled NO, serum IgE and periostin. Although these show potential in guiding the selection of novel interventions for refractory type 2 inflammation in asthma, and in determining if the desired response is being achieved, it is becoming clear that different biomarkers reflect distinct components of the complex type 2 inflammatory pathways. Less progress has been made in identifying biomarkers for use in difficult-to-treat asthma that is not associated with type 2 inflammation. The future is likely to see further biomarker discovery, direct measurements of individual cytokines rather than surrogates of their activity and the increasing use of biomarkers in combination. If the promise of biomarkers is to be fulfilled, they will need to provide useful information that aids clinical decision-making, rather than being 'just another test' for clinicians to order.
Keyword Asthma
Biologics
Biomarkers
Inflammation
Phenotypes
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 14 Mar 2017, 00:24:17 EST by System User on behalf of Learning and Research Services (UQ Library)